These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11891312)

  • 1. Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries.
    Hochgürtel M; Kroth H; Piecha D; Hofmann MW; Nicolau C; Krause S; Schaaf O; Sonnenmoser G; Eliseev AV
    Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3382-7. PubMed ID: 11891312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target.
    Hochgürtel M; Biesinger R; Kroth H; Piecha D; Hofmann MW; Krause S; Schaaf O; Nicolau C; Eliseev AV
    J Med Chem; 2003 Jan; 46(3):356-8. PubMed ID: 12540234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series.
    Stoll V; Stewart KD; Maring CJ; Muchmore S; Giranda V; Gu YG; Wang G; Chen Y; Sun M; Zhao C; Kennedy AL; Madigan DL; Xu Y; Saldivar A; Kati W; Laver G; Sowin T; Sham HL; Greer J; Kempf D
    Biochemistry; 2003 Jan; 42(3):718-27. PubMed ID: 12534284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial design of avian influenza neuraminidase inhibitors containing pyrrolidine core with a reduced susceptibility to viral drug resistance.
    Rungrotmongkol T; Udommaneethanakit T; Frecer V; Miertus S
    Comb Chem High Throughput Screen; 2010 Mar; 13(3):268-77. PubMed ID: 20015013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of 6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylate derivatives as neuraminidase inhibitors.
    Lou J; Yang X; Rao Z; Qi W; Li J; Wang H; Li Y; Li J; Wang Z; Hu X; Liu P; Hong X
    Eur J Med Chem; 2014 Aug; 83():466-73. PubMed ID: 24992074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site.
    Finley JB; Atigadda VR; Duarte F; Zhao JJ; Brouillette WJ; Air GM; Luo M
    J Mol Biol; 1999 Nov; 293(5):1107-19. PubMed ID: 10547289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug screening for influenza neuraminidase inhibitors.
    Liu A; Cao H; Du G
    Sci China C Life Sci; 2005 Feb; 48(1):1-5. PubMed ID: 15844351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QSAR analyses on avian influenza virus neuraminidase inhibitors using CoMFA, CoMSIA, and HQSAR.
    Zheng M; Yu K; Liu H; Luo X; Chen K; Zhu W; Jiang H
    J Comput Aided Mol Des; 2006 Sep; 20(9):549-66. PubMed ID: 17103017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
    Taylor NR; Cleasby A; Singh O; Skarzynski T; Wonacott AJ; Smith PW; Sollis SL; Howes PD; Cherry PC; Bethell R; Colman P; Varghese J
    J Med Chem; 1998 Mar; 41(6):798-807. PubMed ID: 9526556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase.
    Birch L; Murray CW; Hartshorn MJ; Tickle IJ; Verdonk ML
    J Comput Aided Mol Des; 2002 Dec; 16(12):855-69. PubMed ID: 12825619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase.
    Rakers C; Schwerdtfeger SM; Mortier J; Duwe S; Wolff T; Wolber G; Melzig MF
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4312-7. PubMed ID: 25096296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping.
    Brouillette WJ; Atigadda VR; Luo M; Air GM; Babu YS; Bantia S
    Bioorg Med Chem Lett; 1999 Jul; 9(14):1901-6. PubMed ID: 10450950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.
    Prachanronarong KL; Özen A; Thayer KM; Yilmaz LS; Zeldovich KB; Bolon DN; Kowalik TF; Jensen JD; Finberg RW; Wang JP; Kurt-Yilmaz N; Schiffer CA
    J Chem Theory Comput; 2016 Dec; 12(12):6098-6108. PubMed ID: 27951676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus.
    Park JW; Jo WH
    Eur J Med Chem; 2010 Feb; 45(2):536-41. PubMed ID: 19914748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1.
    Rungrotmongkol T; Frecer V; De-Eknamkul W; Hannongbua S; Miertus S
    Antiviral Res; 2009 Apr; 82(1):51-8. PubMed ID: 19428595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
    Watson KG; Cameron R; Fenton RJ; Gower D; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell D; MacDonald SJ; Mason AM; Nguyen V; Tucker SP; Wu WY
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1589-92. PubMed ID: 15006410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.
    Singh A; Soliman ME
    Drug Des Devel Ther; 2015; 9():4137-54. PubMed ID: 26257512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Creation of a generalized model prediction of inhibition of neuraminidase of influenza virus of various strains].
    Mikurova AV; Skvortsov VS
    Biomed Khim; 2018 Jun; 64(3):247-252. PubMed ID: 29964260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 340-cavity in neuraminidase provides new opportunities for influenza drug development: A molecular dynamics simulation study.
    Han N; Mu Y; Miao H; Yang Y; Wu Q; Li J; Ding J; Xu B; Huang Z
    Biochem Biophys Res Commun; 2016 Jan; 470(1):130-136. PubMed ID: 26768362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.